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DOI 10.1016/j.immuni.2009.06.013Def6, also termed SLAT (Tanaka et al.,
2003) or IBP (Gupta et al., 2003), is
a Cdc42-Rac1-specific guanine nucleo-
tide exchange factor (GEF) expressed
predominantly in T cells. Def6/ mice
on a C57BL/6 background are resistant
to T helper 1 (Th1) and Th2 cell-mediated
inflammation (Becart et al., 2007). This
resistance reflects the essential role of
Def6 in promoting T cell receptor (TCR)-
induced Ca2+ release from endoplasmic
reticulum stores and, hence, subsequent
steps in the Ca2+ signaling pathway,
including activation of the transcription
factor NFAT (Becart et al., 2007). More
recently, we demonstrated that Def6 is
activated by Lck-dependent phosphory-
lation of two defined tyrosine residues,
an event that targets Def6 to the plasma
membrane and, more specifically, to the
immunological synapse, in antigen-stimu-
lated T cells (Becart et al., 2008). Further-
more, the Ca2+ signaling function of Def6
leading to Th1 and Th2 cell differentiation
depends on its GEF activity because a
dominant-negativeCdc42mutantblocked
it and, conversely, a constitutively active
Cdc42 mutant rescued the impaired
NFAT activation and Th1-Th2 cell differ-
entiation of Def6/ T cells (Becart et al.,
2008).
A recent paper (Chen et al., 2008)
addressed the role of Def6 in regulat-
ing Th17 cell differentiation and func-
tion. The authors reported that Def6/
(termed by the authors Def6trap/trap)
BALB/c mice crossed to DO11.10 trans-
genic (Tg) mice expressing an MHC class
II-restricted ovalbumin-specific TCR
spontaneously and rapidly develop rheu-
matoid-arthritis-like joint disease and
large vessel vasculitis associated with
enhanced IL-17 and IL-21 production. Of
note, this was an early-onset disease
because the mice started to show signs
of joint disease at 7 weeks of age and
started to die at 3 months, with > 90%
of the mice dead by 12 months. The
authors went on to show that Def6
sequesters, and negatively regulates,IRF-4 (Chen et al., 2008), a transcription
factor recently found to control Th17 cell
differentiation (Brustle et al., 2007). An
earlier report by the same group showed
that Def6/ mice on a mixed 129 3
C57BL/6 background spontaneously de-
velop a systemic autoimmune disorder
characterized by the accumulation of
effector and memory T cells and IgG+ B
cells, profound hypergammaglobuline-
mia, and autoantibody production (Fanzo
et al., 2006).
We question the biological and patho-
logical relevance of the inflammatory
and autoimmune manifestations that
Chen et al. observed in Def6/ mice
(Chen et al., 2008; Fanzo et al., 2006). In
the earlier study (Fanzo et al., 2006), the
mixed genetic background of the mice
could contribute to disease development,
because epistatic interactions between
the non-autoimmune-prone strains 129
and C57BL/6, used for generating gene-
targeted animals, can induce a lupus-like
disease (Bygrave et al., 2004). In that re-
gard, the interchangeable use of Def6/
mice on either a BALB/c or a C57BL/6
background in the latter study (Chen
et al., 2008) is also a potential concern.
In this regard, we have followed Def6/
mice on a C57BL/6 background (Becart
et al., 2007) up to an age of 10 months
and have not observed any signs of
disease. We have also backcrossed
Def6/ mice to BALB/c mice for more
than 10 generations and did not observe
any signs of disease or sudden death up
to an age of 10 months (unpublished
data).
We are also concerned with the recent
study because the enhanced Th17 cell
responses in young animals were only
observed when the Def6/ BALB/c mice
were crossed to DO11.10 TCR-Tg mice
(Chen et al., 2008). Indeed, the authors
state that ‘‘in contrast to Def6trap/trap
DO11.10 mice, young Def6trap/trap
BALB/c mice do not develop obvious
signs of arthritis.’’ Thus, the reported
inflammation (Chen et al., 2008) may be,Immuin our opinion, an artifact of crossing the
Def6/ mice with TCR-Tg mice, raising
two important, but unanswered, ques-
tions. First, what is the relationship
between the antigen specificity of the
TCR-Tg T cells (ovalbumin) and the puta-
tive self-antigen(s) that elicits the autoim-
mune-like inflammatory response? And,
second, is the observed disease a unique
reflection of the DO11.10 transgene
expression or a phenotype that would
be imposed by a TCR transgene of
another antigen specificity? In this regard,
we have followed Def6/ C57BL/6 mice
crossed to OT-II TCR-Tg mice (express-
ing the same antigen specificity as the
DO11.10 mice used by Chen et al.
(2008), i.e., ovalbumin, but on a different
genetic background) up to an age of
10 months, and have not observed any
signs of disease or premature death.
The mice appear healthy and do not
display any signs of ‘‘impaired mobility,’’
which would be expected if they were
suffering from arthritis; similarly, Def6/
C57BL/6 or BALB/c mice, which are not
crossed to TCR-Tg mice, are also healthy
(unpublished data).
More recently, we analyzed the devel-
opment of myelin oligodendrocyte glyco-
protein (MOG)-induced experimental
autoimmune encephalomyelitis (EAE) in
Def6/ C57BL/6 mice. In contrast to the
claim by Chen et al. (2008) that Def6/
mice express enhanced amounts of IL-
17 (and IL-21), we consistently observe
the opposite results. Thus, MOG-primed
Def6/ mice are resistant to EAE devel-
opment and display highly reduced
amounts of IL-17 in the CNS and draining
lymph nodes, consistent with defective
MOG-peptide-induced proliferation and
cytokine (IL-2, IFN-g, IL-17) production
by CD4+ T cells from these mice (unpub-
lished data). Irrespective of the difference
in experimental systems used in different
studies, the resistance to EAE develop-
ment puts into question the validity and
physiological relevance of the observa-
tions in Def6/ DO11.10 mice. Thus,nity 31, July 17, 2009 ª2009 Elsevier Inc. 1
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complex, it is hard for us to see how it
could be a negative regulator of IL-17 in
Def6trap/trap DO11.10 mice and, at the
same time, a positive regulator of IL-17
in Def6/ C57BL/6 mice (unless, of
course, the DO11.10 transgene expres-
sion resulted in an artifact).
We are also concerned about other
data presented in the study by Chen
et al. (2008). As the authors show (Figure 4
of Chen et al. [2008]), and consistent with
other published reports (Ivanov et al.,
2006; Yang et al., 2008) and our own
experience, in vitro stimulation of naive
CD4+ T cells with CD3 and CD28
antibodies in the absence of antigen-
presenting cells or the prerequisite Th17
cell-polarizing cytokines (defined as Th0
conditions by Chen et al. [2008]) fails
to induce substantial IL-17 expression.
However, Figure 7A of the same paper
shows substantial IL-17 expression
by wild-type C57BL/6 mice culturedResponse to Lette
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We are glad to have the opportunity to
clarify the points that Drs. Altman and Be´-
cart have raised regarding our manu-
script. Because Def6 is the official name
of the gene, we will henceforth use this
nomenclature rather than its alternate
names, IBP and SLAT.
Gene deletion that leads to autoimmu-
nity such as lupus-like syndrome occur
only in selected strains of mice because
the development of autoimmunity usually
requires interaction of the effects of the
single gene deletion with those mediated
by various strain-specific background
loci (Jorgensen et al., 2004). We were
thus not surprised to observe, as Altman
and Be´cart have, that Def6trap/trap mice
on a C57BL/6 background do not develop
2 Immunity 31, July 17, 2009 ª2009 Elsevierunder Th0 conditions, which is intrinsi-
cally inconsistent with the data in Fig-
ure 4A, as well as with other published
studies.
In summary, we have doubts about
whether studies documenting enhanced
susceptibility of Def6/mice to systemic
autoimmunity and inflammation (Chen
et al., 2008; Fanzo et al., 2006) reflect
the true biology of Def6, given obvious
issues related to the genetic background
of the mice used in these studies.
REFERENCES
Becart, S., Balancio, A.J., Charvet, C., Feau, S.,
Sedwick, C.E., and Altman, A. (2008). Immunity
29, 704–719.
Becart, S., Charvet, C., Canonigo Balancio, A.J.,
De Trez, C., Tanaka, Y., Duan, W., Ware, C., Croft,
M., and Altman, A. (2007). J. Clin. Invest. 117,
2164–2175.
Brustle, A., Heink, S., Huber, M., Rosenplanter, C.,
Stadelmann, C., Yu, P., Arpaia, E., Mak, T.W.,r from Altman and
pta,1 Partha Biswas,1 Paula Smith,3 Govi
y, New York, NY 10032, USA
ty, New York, NY 10032, USA
SA
a lupus-like syndrome. We have, how-
ever, observed that CD4+ T cells from
Def6trap/trap mice backcrossed onto either
a C57BL/6 or a BALB/c background (for >
10 generations) always exhibit deregu-
lated expression of IL-17 and IL-21 under
neutral conditions in vitro (although the
absolute amounts can vary depending
on the strain). Furthermore, deregulated
expression of IL-17 and IL-21 can be
observed in both transgenic (DO11.10)
and nontransgenic Def6trap/trap T cells,
indicating that this effect is not due to an
artifact imposed by the DO11.10 trans-
gene. For these reasons, we have felt
comfortable using CD4+ T cells from
Def6trap/trap mice on either a C57BL/6 or
a BALB/c background in our manuscript.
Inc.Kamradt, T., and Lohoff, M. (2007). Nat. Immunol.
8, 958–966.
Bygrave, A.E., Rose, K.L., Cortes-Hernandez, J.,
Warren, J., Rigby, R.J., Cook, H.T., Walport,
M.J., Vyse, T.J., and Botto, M. (2004). PLoS Biol.
2, E243.
Chen, Q., Yang, W., Gupta, S., Biswas, P., Smith,
P., Bhagat, G., and Pernis, A.B. (2008). Immunity
29, 899–911.
Fanzo, J.C., Yang, W., Jang, S.Y., Gupta, S., Chen,
Q., Siddiq, A., Greenberg, S., and Pernis, A.B.
(2006). J. Clin. Invest. 116, 703–714.
Gupta, S., Lee, A., Hu, C., Fanzo, J., Goldberg, I.,
Cattoretti, G., and Pernis, A.B. (2003). Hum. Immu-
nol. 64, 389–401.
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro,
C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., and
Littman, D.R. (2006). Cell 126, 1121–1133.
Tanaka, Y., Bi, K., Kitamura, R., Hong, S., Altman,
Y., Matsumoto, A., Tabata, H., Lebedeva, S.,
Bushway, P.J., and Altman, A. (2003). Immunity
18, 403–414.
Yang, X.O., Nurieva, R., Martinez, G.J., Kang, H.S.,
Chung, Y., Pappu, B.P., Shah, B., Chang, S.H.,
Schluns, K.S., Watowich, S.S., et al. (2008). Immu-
nity 29, 44–56.Be´cart
nd Bhagat,2 and Alessandra B. Pernis1,*
We believe that this is a strength of the
system rather than a concern because
the presence of similar abnormalities in
CD4+ T cells from Def6trap/trap mice from
multiple strains strongly supports the
idea that this defect is truly due to the
absence of Def6 and not to the presence
of strain-specific modifiers (or to the pres-
ence of the DO11.10 transgene). Further-
more, our data on the role of Def6 on the
productionof IL-17and IL-21werebacked
by substantial mechanistic studies, which
could not have been influenced by the
strain background of our mice. In partic-
ular, these studies linked Def6 to the
regulation of interferon-regulatory factor-4
(IRF-4), a transcription factorwhose role in
the regulation of IL-17 and IL-21 has been
